Tweet
LOS ANGELES (Reuters) - Two powerful and innovative cholesterol drugs likely to be approved this summer both target the same protein and have been shown to sharply lower LDL in high-risk patients. *But there is at least one significant difference between the two offerings: the dosages in which they will be sold.
More...
More...